Gabrielle Masson

SiteOne Therapeutics is powering up with $100 million to advance its early pipeline of non-opioid therapeutics that target the peripheral nervous system instead of the central nervous system.

Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility of up to $550 million in biobucks.

Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas, including drug discovery, chemistry and medical devices.

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies.

Omeros is putting up its monoclonal antibody up for FDA approval—again. This time, the resubmission will be based on a new data analysis that found

The FDA has denied Zealand Pharma's approval bid for glepaglutide—a possible challenger to Takeda's Gattex—in short bowel syndrome (SBS), citing a lack of evidence.

Pyxis Oncology is shelving a clinical-stage monoclonal antibody to focus on its lead antibody-drug conjugate (ADC) after sharing preliminary results for the ADC last month.

As Cytokinetics' aficamten awaits approval decisions from regulators in the U.S. and China, Sanofi has picked up China rights to the cardiovascular candidate.

Galectin Therapeutics' stock has halved since the company revealed its investigational drug failed to significantly reduce enlarged veins for people with liver scarring.

For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024's reporting.